VIVA23 Presents Outcomes of Late-breaking Science from Abbott's LIFE-BTK, RESOLV FIH Study, and IN.PACT AV Access Trial
The second round of late-breaking clinical trials were presented with results from three studies during the Vascular InterVentional Advances Conference, VIVA23, being held Oct. 30-Nov. 2 in Las Vegas, NV. Notably, results from Abbott’s LIFE-BTK randomized clinical trial (RCT) demonstrated that Esprit BTK (Abbott) reduces disease progression and helps improve medical outcomes compared to balloon angioplasty, the current state of care.
Source: dicardiology.com